Financial Data and Key Metrics Changes - Research and development (R&D) expenses in Q4 2025 totaled $9.9 million, up from $6 million in Q4 2024, with full-year R&D expenses reaching $33.7 million compared to $19.4 million in 2024, primarily due to higher clinical trial and manufacturing costs for soquelitinib and increased personnel costs [4] - The net loss for Q4 2025 was $12.3 million, slightly higher than the net loss of $12.1 million in Q4 2024, with total stock compensation expense increasing to $1.6 million from $0.8 million in the same period [5] - As of December 31, 2025, cash equivalents and marketable securities totaled $56.8 million, up from $52 million at the end of 2024, with pro forma cash including recent financing reaching approximately $246 million, extending the cash runway into Q2 2028 [6][7] Business Line Data and Key Metrics Changes - Significant progress was made in the development of soquelitinib, with promising results from clinical trials in peripheral T-cell lymphoma and atopic dermatitis, indicating its potential as a leading therapy for these conditions [8][9] - The phase I trial results for soquelitinib showed a mean percent reduction in EASI of 72% versus 40% for placebo, with 75% of patients achieving EASI 75 [12] Market Data and Key Metrics Changes - The company is entering 2026 with ongoing enrollment in its phase III PTCL trial and a recently initiated phase II atopic dermatitis trial, with plans to expand into mid-stage trials for other inflammatory diseases later in the year [9][10] - Market research indicates that soquelitinib's profile could significantly advance treatment options for patients with atopic dermatitis, with a unique mechanism of action and favorable safety profile [11][22] Company Strategy and Development Direction - The company aims to leverage the unique mechanism of action of soquelitinib to address multiple inflammatory diseases and cancers, with ongoing trials and data presentations planned for 2026 [9][28] - The strategy includes expanding into additional indications such as hidradenitis suppurativa and asthma, with a focus on the drug's durability and efficacy in patients who have failed prior therapies [27][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term potential of soquelitinib, highlighting its promising clinical data and the opportunity to unlock its full potential in various immune inflammatory diseases [28] - The company is optimistic about the upcoming data readouts from ongoing trials, which are expected to provide further insights into the drug's efficacy and safety [9][34] Other Important Information - The company plans to present additional data from its phase I clinical trials at upcoming medical meetings, emphasizing the importance of biomarker results and the drug's mechanism of action [23][24] - Collaboration with Angel Pharmaceuticals for a phase Ib/II trial in China is ongoing, with initial data expected later this year [24] Q&A Session Summary Question: Regarding the upcoming data readouts for PTCL and the China study - Management anticipates initial data from Angel Pharmaceuticals' trial later this year, with further data expected in mid-2027 from the phase II study [32][34] Question: Expectations for the SID meeting presentation - Management indicated that the presentation will focus on durability and new biomarkers related to soquelitinib's mechanism of action [38][39] Question: Efficacy benchmarks for the phase II trial in hidradenitis suppurativa - Management expects efficacy to be comparable or better than existing biologics, with ongoing assessments to determine optimal dosing [42] Question: Insights on the ALPS trial and its implications for other indications - Management noted that while ALPS results are promising, they do not directly predict outcomes for other diseases but indicate the drug's potential in managing aberrant autoinflammatory responses [68] Question: Durability of response in the phase II trial - The phase II trial includes a follow-up period of 90 days post-treatment, although the primary endpoint focuses on EASI scores at 12 weeks [94][96] Question: Target populations for the upcoming asthma study - Management is considering a broad patient population for the asthma study, without restricting to specific subtypes, and is still finalizing the study protocol [100]

Financial Data and Key Metrics Changes - Research and development (R&D) expenses in Q4 2025 totaled $9.9 million, up from $6 million in Q4 2024. For the full year 2025, R&D expenses were $33.7 million compared to $19.4 million in 2024, primarily due to higher clinical trial and manufacturing costs associated with soquelitinib and increased personnel costs [4][5] - The net loss for Q4 2025 was $12.3 million, slightly higher than the net loss of $12.1 million in Q4 2024. Non-cash losses included $0.7 million in Q4 2025 and $2.2 million in Q4 2024 from equity method investments [5] - As of December 31, 2025, cash equivalents and marketable securities totaled $56.8 million, an increase from $52 million at the end of 2024. Following a public offering, pro forma cash was approximately $246 million, extending the cash runway into Q2 2028 [6][7] Business Line Data and Key Metrics Changes - Significant progress was made in the development of soquelitinib, with promising results from clinical trials in peripheral T-cell lymphoma and atopic dermatitis. The company is entering 2026 with ongoing enrollment in a phase 3 PTCL trial and a newly initiated phase 2 atopic dermatitis trial [8][9] - The phase 1 trial results for soquelitinib showed a mean percent reduction in EASI of 72% versus 40% for placebo, with 75% of patients achieving EASI 75 [12][13] Market Data and Key Metrics Changes - The company is focusing on expanding soquelitinib's application in various inflammatory diseases, including hidradenitis suppurativa and asthma, with plans to initiate trials later in 2026 [9][26] - The market research indicates that soquelitinib's profile could significantly advance treatment options for patients with atopic dermatitis, particularly due to its oral administration and novel mechanism of action [11][21] Company Strategy and Development Direction - The company aims to leverage the unique mechanism of action of soquelitinib to address multiple inflammatory diseases and cancers, with a strong focus on clinical data and biomarker analysis to support its therapeutic potential [21][27] - The strategy includes expanding into mid-stage trials for other inflammatory diseases and maintaining a robust pipeline for soquelitinib, which is expected to be a leading option for treating moderate to severe atopic dermatitis [9][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term potential of soquelitinib, highlighting its safety profile and efficacy in patients who have failed prior therapies. The company anticipates significant data readouts in 2026 that will inform future development [9][27] - The management team emphasized the importance of ongoing clinical trials and the potential for soquelitinib to provide durable responses in patients, which could change treatment paradigms in inflammatory diseases [27][98] Other Important Information - The company plans to present additional data from the phase 1 clinical trial at the Society for Investigative Dermatology annual meeting, focusing on biomarker results and durability of response [22] - The phase 2 trial in atopic dermatitis will enroll 200 patients, with results expected in mid-2027, while the PTCL trial will have an interim analysis later this year [24][25] Q&A Session Summary Question: Regarding the upcoming data readouts for PTCL and the China study - Management anticipates initial data from Angel Pharmaceuticals' trial later this year, with further data expected in 2027. The PTCL trial will have an interim review later this year [32][34] Question: Expectations for the SID meeting presentation - Management indicated that the durability of response and new biomarkers will be key focuses of the presentation [38][39] Question: Efficacy benchmarks for the phase 2 trial in hidradenitis suppurativa - Management expects efficacy to be comparable or better than existing biologics in the market [42] Question: Updates on the phase 2 trial in atopic dermatitis - The phase 2 trial is blinded and randomized, with no interim data expected until completion. However, updates from the Angel trial will provide interim insights [52][53] Question: Insights on the ALPS trial and its implications - Management noted that while ALPS results are promising, they do not directly predict outcomes for other indications but indicate the drug's activity in autoimmune responses [70][71] Question: Durability of response in the phase 2 trial - The phase 2 trial includes a follow-up period of 90 days post-treatment, but the primary endpoint will focus on EASI scores at 12 weeks [96][99] Question: Asthma trial design considerations - Management is considering a broad patient population for the asthma trial, without restricting to TH2 high patients, and is still finalizing the protocol [100][102]

Financial Data and Key Metrics Changes - Research and development (R&D) expenses in Q4 2025 totaled $9.9 million, up from $6 million in Q4 2024, with full-year R&D expenses reaching $33.7 million compared to $19.4 million in 2024, primarily due to higher clinical trial and manufacturing costs for soquelitinib and increased personnel costs [4] - Net loss for Q4 2025 was $12.3 million, slightly higher than the net loss of $12.1 million in Q4 2024, with total stock compensation expense increasing to $1.6 million from $0.8 million in the same period [5] - As of December 31, 2025, cash equivalents and marketable securities totaled $56.8 million, up from $52 million at the end of 2024, with pro forma cash including net proceeds from a public offering amounting to approximately $246 million, extending the cash runway into Q2 2028 [6] Business Line Data and Key Metrics Changes - Significant progress was made in the development of soquelitinib, with ongoing enrollment in the phase 3 trial for peripheral T-cell lymphoma (PTCL) and a recently initiated phase 2 trial for atopic dermatitis [9] - The phase 1 trial results for soquelitinib in atopic dermatitis showed a mean percent reduction in EASI of 72% compared to 40% for placebo, with 75% of patients achieving EASI 75 [12] Market Data and Key Metrics Changes - The company is entering 2026 with strong investor interest, highlighted by a $200 million financing, reflecting confidence in the potential of soquelitinib and ITK inhibition [8] - The phase 1 trial data presented at the ASH annual meeting indicated that soquelitinib could be a leading therapy for atopic dermatitis and other inflammatory diseases, with a favorable comparison to existing treatments [25] Company Strategy and Development Direction - The company plans to expand its clinical trials for soquelitinib into mid-stage trials for other inflammatory diseases such as hidradenitis suppurativa and asthma later in the year [9] - The strategy focuses on leveraging the unique mechanism of action of soquelitinib to address multiple inflammatory diseases, with ongoing research into its safety and efficacy [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term potential of soquelitinib across various indications, emphasizing the drug's unique properties and the promising clinical data supporting its use [27] - The company is optimistic about the upcoming data readouts from ongoing trials, which are expected to provide further insights into the drug's efficacy and safety [33] Other Important Information - The company is collaborating with Angel Pharmaceuticals for a phase 1b/2 trial in China, which is expected to provide additional data on soquelitinib's efficacy in atopic dermatitis [21] - The phase 2 trial for atopic dermatitis is set to enroll 200 patients, with results anticipated in mid-2027 [24] Q&A Session Summary Question: Regarding the upcoming data readouts for PTCL and the China study - Management indicated that initial data from Angel Pharmaceuticals' trial will be available later this year, with further data expected in 2027 [31][33] Question: Expectations for the SID meeting presentation - Management highlighted that the presentation will focus on durability and new biomarkers related to soquelitinib's mechanism of action [37] Question: Insights on the phase 2 trial in hidradenitis suppurativa - Management stated that they expect efficacy to be comparable or better than existing biologics, with ongoing assessments to determine optimal dosing [40] Question: Comments on the ALPS trial and its implications - Management noted that while results from the ALPS trial are promising, they do not directly predict outcomes for other autoimmune diseases [68] Question: Enrollment dynamics in the PTCL trial - Management confirmed that the trial is progressing well, with patients being randomized to receive either soquelitinib or standard care options [72][75] Question: Durability of response in the phase 2 trial - Management confirmed that the phase 2 trial includes a follow-up period to assess durability, although the primary endpoint remains the EASI score at 12 weeks [93]

Summary of aTyr Pharma Conference Call Company Overview - **Company**: aTyr Pharma - **Focus**: Development of therapies targeting inflammation and fibrosis through tRNA synthetase biology [1][2] Core Points and Arguments Pipeline and Lead Therapy - **Lead Therapy**: Efzofitimod, which has completed a Phase 3 trial and is scheduled for a US FDA Type C meeting in mid-April [2][3] - **Pipeline**: Includes ATYR0101, targeting myofibroblasts for fibrosis, expected to enter the clinic next year [3] Target Conditions - **Primary Focus**: Interstitial lung disease (ILD), particularly sarcoidosis and scleroderma-related ILDs [4][5] - **Market Potential**: ILD market estimated at up to $5 billion, with current therapies being toxic and not disease-modifying [5] Mechanism of Action - **Efzofitimod**: Targets innate immunity at inflammation sites, down-regulating pro-inflammatory signals through interaction with macrophages and Neuropilin-2 receptor [6][8] - **Treatment Approach**: Aims to be a steroid-sparing agent, reducing reliance on steroids which are currently the legacy treatment [11][26] Clinical Trial Results - **Phase III Trial**: Enrolled 268 patients across multiple countries, testing different dosages of efzofitimod [12] - **Steroid Reduction**: Nearly 80% reduction in steroid use observed, although the primary endpoint was not statistically significant [16][18] - **Quality of Life Improvements**: Significant improvements in patient-reported outcomes, particularly in lung symptoms and overall health [19][21] Safety and Tolerability - **Safety Profile**: Efzofitimod well-tolerated with low rates of serious adverse events [25][26] - **Antibody Response**: No concerning treatment-boosted anti-drug antibodies observed [26] Future Directions - **FDA Meeting**: Anticipated discussions on the viability of the program and potential next steps, including the possibility of running another trial [32][34] - **Scleroderma Trial**: Ongoing trial for scleroderma-related ILD, with promising early results in skin symptom improvement [30][31] Additional Important Content - **Changing Treatment Practices**: Efzofitimod is influencing treatment patterns, with clinicians actively reducing steroid use based on trial data [27][28] - **Operational Readiness**: aTyr Pharma has demonstrated capability in enrolling and executing clinical trials, positioning itself well for future studies [42] This summary encapsulates the key points discussed during the conference call, highlighting aTyr Pharma's innovative approach to treating inflammation and fibrosis through efzofitimod and its implications for future clinical practice and regulatory discussions.

Core Viewpoint - Tiziana Life Sciences is advancing its lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, which has shown promising results in treating neuroinflammatory and neurodegenerative diseases, particularly in patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) [1][2][3]. Group 1: Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies using transformational drug delivery technologies [4]. - The company’s lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development, demonstrating a favorable safety profile and clinical response in previous studies [4]. - Tiziana's intranasal approach aims to improve efficacy, safety, and tolerability compared to traditional intravenous delivery methods [4]. Group 2: Product Development - Foralumab has been administered to 14 patients with na-SPMS in an open-label Expanded Access Program, with all patients showing either improvement or stability of disease within six months [2]. - The drug is also undergoing a Phase 2a randomized, double-blind, placebo-controlled trial to further assess its efficacy in patients with non-active secondary progressive multiple sclerosis [2][3]. - The immunomodulation potential of intranasal foralumab represents a novel treatment avenue for neuroinflammatory and neurodegenerative diseases [3]. Group 3: Executive Actions - Mr. Gabriele Cerrone, the Executive Chairman and Founder of Tiziana, has purchased 97,687 common shares, increasing his total holdings to 43,374,830 shares, which constitutes 36.08% of the company's issued share capital [1].

Core Viewpoint - Tiziana Life Sciences is celebrating a significant milestone by ringing the Nasdaq Closing Bell, highlighting its advancements in immunomodulation therapies, particularly its lead candidate, intranasal foralumab, which targets neurodegenerative and inflammatory diseases [1][2][3]. Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies using transformational drug delivery technologies, specifically intranasal delivery methods [6]. - The company’s lead candidate, intranasal foralumab, is the only fully human anti-CD3 monoclonal antibody currently in clinical development, showing a favorable safety profile and clinical response in patients [5][6]. Product Development - Intranasal foralumab aims to improve efficacy, safety, and tolerability compared to traditional intravenous methods, targeting diseases such as multiple sclerosis, Alzheimer's disease, and ALS [2][6]. - The company has recently achieved significant milestones, including the dosing of the first patient in its Phase 2 Alzheimer's trial and expansions in other key studies [3][4]. Clinical Trials - Foralumab has been administered to 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) in an open-label program, with all patients showing either improvement or stability of disease within six months [4]. - The drug is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled trial for non-active secondary progressive multiple sclerosis [4].

Core Viewpoint - Tiziana Life Sciences has initiated a Phase 2 clinical trial for intranasal foralumab, targeting early Alzheimer's disease, marking a significant step in exploring immunomodulatory therapies for neuroinflammation [1][3][7]. Group 1: Clinical Trial Details - The Phase 2 trial is randomized and placebo-controlled, assessing the safety, tolerability, and potential efficacy of intranasal foralumab as both a monotherapy and in combination with FDA-approved anti-amyloid therapies, lecanemab or donanemab [4]. - Primary endpoints of the trial include neuroinflammation measured by TSPO-PET imaging, cognitive function, and changes in amyloid and tau biomarkers, with interim data expected in 2026 [4]. Group 2: Scientific Rationale - TSPO-PET imaging data indicates persistent microglial activation in Alzheimer's patients, even after treatment with anti-amyloid therapies, highlighting the need for therapies that address residual neuroinflammation [2]. - Intranasal foralumab is designed to modulate immune responses and reduce activated microglia, potentially slowing disease progression in early Alzheimer's disease [2][3]. Group 3: Company Insights - Gabriele Cerrone, Chairman & Founder, emphasized the importance of this trial in exploring a novel approach to Alzheimer's treatment, building on previous data showing foralumab's ability to reduce microglial activation in multiple sclerosis patients [3]. - Ivor Elrifi, CEO, expressed enthusiasm for the rapid progress from enrollment to first patient dosing, reflecting the urgent need for new treatment strategies beyond amyloid clearance [3]. Group 4: About Foralumab - Foralumab is a fully human anti-CD3 monoclonal antibody that stimulates T regulatory cells when administered intranasally, with previous studies showing positive outcomes in patients with non-active secondary progressive multiple sclerosis [5][6]. - It is the only fully human anti-CD3 monoclonal antibody currently in clinical development, representing a novel treatment avenue for neuroinflammatory and neurodegenerative diseases [6]. Group 5: Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies using alternative drug delivery technologies, aiming to improve efficacy, safety, and tolerability compared to traditional intravenous delivery methods [6][8].

Core Viewpoint - Tiziana Life Sciences has announced the withdrawal of its proposed public offering of common shares due to unfavorable market conditions [1]. Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative immunomodulation therapies, particularly through its lead candidate, intranasal foralumab, which is a fully human anti-CD3 monoclonal antibody [3]. - The company aims to improve the efficacy, safety, and tolerability of immunotherapy by utilizing alternative drug delivery methods, specifically through nasal administration [3]. - Tiziana's technology for alternative routes of immunotherapy has been patented, with several applications pending, indicating potential for broad pipeline applications [3]. Product Information - Foralumab is the only fully human anti-CD3 monoclonal antibody currently in clinical development, showing promise in stimulating T regulatory cells when administered intranasally [5][6]. - In an open-label intermediate-sized Expanded Access Program, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been treated, with all patients showing either improvement or stability of disease within six months [5]. - Foralumab is also undergoing a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial for patients with non-active secondary progressive multiple sclerosis [5].

Core Viewpoint - Tiziana Life Sciences has initiated enrollment for a Phase 2 clinical trial of intranasal foralumab, targeting early Alzheimer's disease, with the first patient expected to be dosed next week [1][10]. Group 1: Clinical Trial Details - The Phase 2 trial will assess intranasal foralumab as both a monotherapy and in combination with FDA-approved anti-amyloid therapies, lecanemab or donanemab, in early Alzheimer's patients [2][9]. - Baseline assessments including cognitive testing and TSPO-PET imaging have been completed for initial participants [2][11]. - Key endpoints of the trial will include measures of neuroinflammation, cognitive function, and changes in biomarkers related to amyloid and tau pathology [11]. Group 2: Scientific Insights - New TSPO-PET imaging evidence shows persistent microglial activation in an Alzheimer's patient treated with lecanemab, indicating ongoing neuroinflammation despite amyloid plaque reduction [3][4]. - Dr. Howard Weiner emphasized that clearing amyloid does not eliminate the brain's inflammatory response, suggesting that intranasal foralumab may effectively address this residual neuroinflammation [6][10]. Group 3: Mechanism of Action - Intranasal foralumab is designed to induce regulatory T cells to migrate to the brain, potentially calming activated microglia and reducing neuroinflammation [6][10]. - The therapy aims to provide an additive or synergistic benefit when used alongside anti-amyloid treatments by targeting both amyloid pathology and persistent microglial inflammation [9][10]. Group 4: Company Overview - Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies using alternative drug delivery technologies, with intranasal foralumab being the only fully human anti-CD3 monoclonal antibody in clinical development [13]. - The company aims to improve efficacy, safety, and tolerability of treatments compared to traditional intravenous delivery methods [13].

Financial Data and Key Metrics Changes - The company is focused on the upcoming data readout for setrusumab, which is expected by the end of the year or early January, marking a significant near-term value driver [2][34] - The company has achieved a 67% reduction in fracture rates from baseline in the Orbit trial, indicating strong efficacy of setrusumab [8][15] Business Line Data and Key Metrics Changes - The company is advancing its gene therapy programs, particularly for Sanfilippo and GSDIa, with both expected to file for approval within the PRV window by the end of September [38][91] - The company is also conducting a seamless phase I/II/III study for Wilson disease, aiming to demonstrate the efficacy of its gene therapy in reducing the need for chelators [52][54] Market Data and Key Metrics Changes - The potential market for Osteogenesis Imperfecta (OI) is estimated at 60,000 patients in the covered geographies, presenting a unique opportunity for the company [3][4] - For Sanfilippo, the patient population is estimated between 3,000 and 5,000, while GSDIa has around 6,000 patients, indicating significant market potential for these gene therapies [42] Company Strategy and Development Direction - The company aims to leverage lessons learned from the successful launch of Crysvita to enhance the launch of setrusumab for OI [4] - The strategy includes not compromising data quality to meet regulatory deadlines, emphasizing the importance of robust data packages for successful product launches [30][92] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming data readouts and the potential for successful regulatory filings, highlighting the importance of these products to the company's future [34][92] - The company is actively exploring the use of AI to streamline data analysis and document preparation, aiming to enhance efficiency in the approval process [32] Other Important Information - The company has successfully monetized a deal with OMERS for Crysvita, which is expected to provide financial flexibility as it approaches profitability [91] - The company is committed to ensuring that all patient populations affected by Angelman syndrome can benefit from its therapies, aiming for a full label upon approval [87] Q&A Session Summary Question: What is the timeline for the data readouts for setrusumab? - The company has defined the end of the year as December or January for the data readouts, indicating a near-term timeline [34] Question: How does the company view the efficacy of bisphosphonates compared to setrusumab? - Management estimates the treatment effect of bisphosphonates to be around 20%, while setrusumab has shown a 67% reduction in fracture rates, indicating a significant improvement [15][16] Question: What is the company's approach to regulatory filings for Sanfilippo and GSDIa? - The company plans to refile for Sanfilippo early next year and is on track to complete the rolling BLA for GSDIa this month, both aiming for PDUFA dates within the PRV window [38][91] Question: How does the company plan to address the potential for opportunistic infections with immunomodulation therapies? - Management indicated that while there are concerns with immunosuppressants like sirolimus, the focus is on optimizing efficacy and safety through careful study design [67]